welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies
source: Pharmacotherapy
year: 2017
authors: Reinig AM, Mirzaei S, Berlau DJ
summary/abstract:Duchenne muscular dystrophy (DMD) is a genetic neuromuscular disease that primarily affects young males. Patients with DMD are unable to produce dystrophin, a crucial protein found in myocytes, leading to a loss of muscle support and integrity. Corticosteroids are the standard supportive treatment for DMD; however, there is a high demand to expand the number of safe, effective pharmacologic options. Recently a surge of new therapeutics for DMD is offering hope to patients. A variety of these new medications, such as stop codon readthrough agents, exon-skipping agents, and utrophin modulators, aim to replace dystrophin in myocytes. Other new therapeutics aim to prevent or repair muscle damage caused by the absence of dystrophin. This review provides an update on the medications being investigated in DMD.
organisation: Regis University Rueckert-Hartman College for Health ProfessionsDOI: 10.1002/phar.1909
read more full text source
rareRelated
-
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy PatientsThis study is designed to assess the eff...
-
Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential...Catabasis Pharmaceuticals, Inc., a clini...
-
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular...Pfizer Inc. has initiated a Phase 1b cli...
-
Kathryn Wagner, MD, PhD – Progress in Better Treatments for Muscular Dystrophyhttps://www.youtube.com/watch?v=0yC4_lEn...
-
Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy – ACE Inhibitor Therapy TrialThis trial intends to evaluate myocardia...
-
Evox Therapeutics wins funding from Duchenne UK to explore exosome-mediated delivery of dystrophinEvox Therapeutics Ltd, a leading exosome...
-
Development of a CRISPR-based gene therapy approach targeting the large exon 45-exon 55 mutation hotspot in DMD geneGene replacement and exon skipping thera...